Journal article
Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada
Clinical Infectious Diseases, Vol.37(8), pp.1139-1142
2003
Abstract
Although information on efficacy and adverse drug reactions is lacking, ribavirin has been used empirically for the treatment of severe acute respiratory syndrome (SARS). We report common adverse events in 110 patients with suspected or probable SARS who were treated with ribavirin. Sixty-one percent of the patients had evidence of hemolytic anemia, and hypocalcemia and hypomagnesmia were reported in 58% and 46% of patients, respectively.
Details
- Title
- Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada
- Authors/Creators
- S.R. Knowles (Author/Creator)E.J. Phillips (Author/Creator)L. Dresser (Author/Creator)L. Matukas (Author/Creator)
- Publication Details
- Clinical Infectious Diseases, Vol.37(8), pp.1139-1142
- Publisher
- University of Chicago Press
- Identifiers
- 991005544769607891
- Copyright
- © 2003 by the Infectious Diseases Society of America
- Murdoch Affiliation
- Murdoch University
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
238 File views/ downloads
36 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Citation topics
- 1 Clinical & Life Sciences
- 1.104 Virology - General
- 1.104.1353 Coronavirus Research
- Web Of Science research areas
- Immunology
- Infectious Diseases
- Microbiology
- ESI research areas
- Immunology